Article
Treatment for C difficile Shows Promising Potential in First-in-Human Phase 1 Trial
Author(s):
A first-in-human trial evaluating the safety, pharmacokinetics, and fecal microbiome effects of a novel DNA polIIIC inhibitor demonstrated the antibacterial’s promise as a potential treatment alternative to vancomycin for the treatment of Clostridioides difficile.
A first-in-human trial evaluating the safety, pharmacokinetics, and fecal microbiome effects of a novel DNA polIIIC inhibitor demonstrated the antibacterial’s promise as a potential treatment alternative to vancomycin for the treatment of Clostridioides difficile.
In a presentation at IDWeek 2019, a team of investigators detailed the 3-part phase 1, double-blind, randomized healthy volunteer trial of the narrow-spectrum antibacterial ACX-362E.
The trial evaluated the safety profile, food effect, and systemic/stool pharmacokinetics of escalating single (150, 300, 600, and 900 mg) and multiple (300 and 450 mg) doses oral ACX-362E compared with placebo. Investigators observed no moderate, severe, cumulative, or dose-limiting adverse events leading to discontinuation, and ACX-362E was generally well-tolerated at all dose levels.
Read the full article by our sister publication, Contagion, at ContagionLive.com.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
